Interventions of Interest
- Tabelecleucel (Pierre Fabre)
The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle.
Final Documents
For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org.
View the Key Stakeholder List.
ICER’s Vice President of Research Foluso Agboola, MBBS, MPH:
“EBV+ PTLD is a rare and often fatal cancer associated with solid organ transplant and stem cell transplant.
Unfortunately, approximately half of EBV+ PTLD cases do not respond to initial treatment or relapse, resulting
in a poor prognosis. The limited evidence on tabelecleucel suggests that it provides important clinical benefits
in patients with relapsed refractory EBV+ PTLD, extending survival for patients who otherwise do not usually
survive beyond a few weeks to months, with few harms.”
Public Comments
Closed